Here’s a startling fact: Two critical parliamentary studies are quietly shaping Canada’s future in medical innovation, pandemic preparedness, and access to medicines—yet they’re flying under the radar. But here’s where it gets controversial: these studies could perpetuate a troubling trend of the Canadian government prioritizing private enterprise over public health when it comes to investing in research and development (R&D) and biomanufacturing. If you think this doesn’t affect you, think again—it could determine who gets life-saving medicines and at what cost.
The first study, underway at the Standing Committee on Science and Research (SRSR), is deceptively titled Private Sector Investment in Research and Development in Canada. And this is the part most people miss: it’s actually about funneling publicly funded research from Canadian universities into the private sector to boost the economy. While this might sound like a win-win, it raises a critical question: Who controls the outcomes of this research? Historically, private interests have held the reins, deciding who accesses the resulting medicines and at what price—a decision that can literally mean life or death. For instance, innovations like the monoclonal antibody treatment bamlanivimab and lipid nanoparticle technology for mRNA vaccines, both born from publicly funded research at the University of British Columbia, ended up benefiting private companies more than the public. Canada even found itself paying tens of millions for a drug it helped develop.
The second study, soon to begin at the Standing Committee on Health (HESA), focuses on Canada’s Pharmaceutical Sovereignty. COVID-19 exposed Canada’s vulnerabilities, from drug shortages to reliance on foreign manufacturers. Despite massive public investment in biomanufacturing, much of it subsidized private companies, many based abroad. Here’s the irony: Canada is trying to achieve pharmaceutical independence by handing control to foreign entities. Does this make sense? Or is it a recipe for continued dependence?
Take the Biologics Manufacturing Centre (BMC) in Montreal, a publicly owned facility that’s been sitting idle since 2022, despite receiving $17 million annually. Its failure as a contract manufacturer for commercial interests, like the botched Novavax deal, highlights a glaring issue: Canada’s biomanufacturing investments aren’t aligned with public health needs. Instead of appeasing private interests, why not use facilities like the BMC to produce essential medicines for both domestic use and global health emergencies?
Here’s a thought-provoking question: Should Canada continue subsidizing a profit-driven industry, or should it prioritize public health by filling the gaps commercial interests ignore? For example, many WHO-recognized Essential Medicines, including treatments for deadly diseases like tuberculosis, aren’t available in Canada because they’re deemed unprofitable. Is this truly exercising pharmaceutical sovereignty?
The same issue plagues vaccine development. Canada’s National Microbiology Laboratory (NML) has produced groundbreaking vaccines, like the first effective Ebola vaccine. Yet, these innovations often get stuck in licensing limbo or are priced out of reach for those who need them most. Meanwhile, foreign governments are funding the advancement of Canadian-developed vaccines, leaving Canada on the sidelines.
Canada has a chance to shift its strategy. Instead of hoping private interests will align with public health, the government could proactively identify and address gaps. For a fraction of its current spending, it could produce critical medicines like mAb treatments, ensuring domestic biosecurity while contributing to global health. This approach wouldn’t just save lives—it would assert Canada’s pharmaceutical sovereignty in a way that truly prioritizes people over profits.
As these committees deliberate, let’s hope they recognize the urgency of this shift. But what do you think? Is Canada’s current approach to R&D and biomanufacturing sustainable? Or is it time to rethink how public investment serves the public? Share your thoughts in the comments—this conversation is too important to ignore.
